FDA Fast Tracks Pfizer Vaccine Candidate

Pfizer Inc. reports that the US Food and Drug Administration (FDA) has granted Fast Track designation to the company's investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). The vaccine, designed to prevent a difficult-to-treat healthcare associated infection, is currently in Phase II clinical development.

The FDA's Fast Track approach is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address an unmet medical need.

Source: Pfizer

Leave a Reply

Your email address will not be published. Required fields are marked *